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The Role of Integrin Alpha 6 on Tumor
Metastasis
An Honors Thesis submitted in partial fulfillment of the requirements
for Honors in Biology

By
Shauntell Luke
Under the mentorship of Dr. Vinoth Sittaramane
ABSTRACT
Cancer research is a large topic in science, because over 14 million people are diagnosed
worldwide, and of those, 8 million will die annually. Traditional therapies are the mainstays of treatment
strategies, but a cure less invasive or with less side effects have not yet been identified. In order to
develop a better cure, we need to understand the tumor and molecules present in its tissues. Integrins, cell
surface proteins that aid in cell communication, have been found in the tumor tissues of several types of
cancers, including prostate, lung and bone. Integrin alpha-6 (ITGA6), in particular, has been found to
have a large effect on the progression of tumor metastasis. In tumor tissues, we have seen an
overexpression of the ITGA6 that leads to tumor metastasis and overall tumor progression. We have also
seen an in vitro cleaving mechanism, in which only a cleaved, or extracellular portion of the protein is
expressed in the microenvironment. To develop a therapeutic strategy, it is important to understand the
role of ITGA6 in tumor development. Using a humanized zebrafish model, we hypothesized that
increasing ITGA6 and cleaving ITGA6 will increase tumor metastasis. To study this question, we
overproduced ITGA6 by injecting human ITGA6 RNA and reduced the gene using the morpholinos. We
also injected cleaved human ITGA6 RNA and non-cleaved, or mutated ITGA6 RNA that could be not
removed from the surface of the cell. We then injected human prostate cancer cells and allowed a human
tumor microenvironment to develop over two days. Using confocal imaging, we visualized non-metastatic
versus metastatic embryos. We utilized a t-test and found p-values of <.01 when comparing the full length
ITGA6 and cleaved ITGA6 to the control. We concluded that increased and cleaved integrin alpha 6
allow for the cell to develop cancerous abilities such as increased aggressiveness, motility through the
ECM, invasion and metastasis in blood vessels to create secondary tumors. Studies are now showing that
ITGA6 can be used a biomarker, a molecule that can predict the susceptibility of several cancers. In the
future, we would like to use ITGA6 manipulations and drug screenings in a favorable zebrafish model to
create a preventative strategy for cancer.
Keywords: cancer, metastasis, integrins, prostate, Zebrafish
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Introduction
1. Cancer
Cancer is the foremost generic word that creates severe panic within a person, family, or
community. Cancer [Figure 1] is defined as a disease characterized by abnormal growth of cells
due to uncontrollable cell division. It can be
caused by external factors that include
one’s behavior such as smoking, drinking,
diet, and exercise. It can also be caused by
internal factors such as genetics, hormones,
and immune conditions (1). This panic is
supported by the gruesome reality of cancer
with approximately 14 million people being
diagnosed worldwide each year (2,3). Of
those diagnosed, over 50% of these cases
Figure 1. This schematic shows the overall progression
of tumor development, where a cancer cell loses
adhesion to the tissue. The cell invades and
metastasizes into the blood vessels creating secondary
tumors.
http://www.nature.com/nrc/journal/v5/n1/images/nrc1527f4.jpg

come from undeveloped countries. The most
prominent types of cancer include lung,
female breast, bowel and prostate cancer,
with 4 in 10 cases stemming from one of
these groups (3). Of those diagnoses, over

half, 8 million, will die. Most deaths come from lung, liver, bowel, and stomach cancer, with
lung cancer accounting for one-fifth of all deaths (3). In the female population, breast cancer is
the most deadly. Approximately 240,000 new cases will be diagnosed in women, and 40,000
women will die (2). Prostate cancer, however, is very prevalent in males, being the second most
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common cancer in males after skin cancer. In the United States, there are approximately 230,000
new cases each year and over 3 million people living with the cancer today (2). The death rate of
prostate cancer is one of the most with about 12% (1 in 38) of all diagnoses ending fatally (1).
1.1 Cancer Management
In order to have the best chances of managing a patient’s cancer, early diagnosis and
appropriate therapeutic strategies are the two major steps to effectively fight the disease (4).
Early diagnosis of the cancer gives a better chance of it not already becoming too big or
spreading to other vital organs (4). An important tool in early diagnosis is the use of biomarkers.
Biomarkers are any substance or molecule that can indicate the presence of cancer in the body
(4). In addition to early diagnosis, it is vital to use the most appropriately fitting therapeutic
strategy to treat the three factors that cause cancer to be so difficult to control.
1.2 Three Factors of Cancer: Angiogenesis, Metastasis, and Cancer Stem Cells
First, angiogenesis occurs in a patient. Angiogenesis [Figure 2] is the creation of blood
vessels that stem from the tumor into the blood stream (5).
These blood vessels allow the tumor to
receive nutrients that are pertinent to
Figure 2. Newly formed blood
vessels are stemming from the tumor
into the microenvironment created
via angiogenesis.
http://systemsbiology.case.edu/OLD%20
WEBSITE%20STUFF/images/angiogen
esis/angiogenesis_pic1.jpg

its growth and survival. They are also
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a pathway for the cancer cells of the tumor to travel through the bloodstream to reach other
organs (5).
The dissemination of cancer cells [Figure 3] throughout the body using these blood
vessels is known as metastasis, the second factor of cancer (6).
Metastasis is the most deadly element of
Figure 3. The cells moving
from the primary tumor into the
blood stream via newly formed
blood vessel into a previous
blood vessel is the process
known as metastasis that creates
secondary tumors in another
tissues.

related to cancer. Once cancer cells reach other

http://www.nature.com/nrc/journal/
v5/n1/images/nrc1527-f4.jpg

cancer as it
is the cause
of over
90% of the
deaths
organs,

they have the potential to create secondary tumors, facilitated by cancer stem cells, the third and
least understood mechanism of cancer (6).

Cancer stem cells (CSC) [Figure 4] are similar
Figure 4. The purple, orange, and
pink cells signify cancer cells
with variations. The green cells
represent cancer stem cells that
have the ability to form new
tumor masses in different tissues.

to normal, human
stem cells, because
they are self-renewing
(7).

http://www.nature.com/labinvest/jour
nal/v91/n5/images/labinvest201150f1
.jpg
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These cells originate from stem cells or progenitors, targeted stem cells specific to cancer (7,10).
In a tumor, there can exist multiple populations of CSCs or they can co-exist among normal
cancerous cells (10). CSCs can influence the start of metastasis, as well as, relapse in a patient
that is in remission (10).
1.3 Traditional Treatments
Modern, conventional therapeutic strategies that try to control the factors of cancer
include chemotherapy, radiation, and surgery. Chemotherapy uses anti-cancer drugs to shrink
and eliminate the tumor (8). Radiation uses ionizing radiation to kill cancer cells by damaging
their DNA (9). Surgery for cancer patients has a number of different uses, ranging from
diagnostic to curative surgeries (10). Both chemotherapy and radiation have severe adverse
effects, because the strategies are non-specific. They both kill all types of cells, which leads to
severe damage in other vital tissues and organs (9,10). Surgery can and very often leads to
deadly infections that can kill the patient (10). What all three therapeutic strategies have in
common is that they aim to treat cancer, but they have no mechanism to cure the cancer (9,10).
In order to have the best chance of curing any type of cancer, a molecule needs to exist that can
be a biomarker, as well as, be used appropriately as a therapeutic strategy (10). Integrinα6
(ITGA6) is a molecule that is a biomarker for several types of cancer and can potentially be used
as a therapeutic strategy to treat cancer (10).
2. Integrinα6 in Cancer
2.1 ITGA6 Protein
ITGA6 is a part of a group of transmembrane proteins that aid in cell adhesion, cell-tocell communication, intracellular communication, and act as ECM receptors that were
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discovered approximately 25 years ago (11). These proteins are most notably known for binding
to extracellular glycoproteins such as laminin, vascular cell adhesion molecule-1 and collagen, to
enhance cell adhesion, proliferation, cell differentiation, and cell migration (11). Integrins are
made of two subunits, alpha and beta, that are bound via noncovalent interactions to make
heterodimeric proteins (6, 11). Integrins vary in size, depending on higher order function, and
have been found in all mammals and most fish, such as sponges, nematodes, zebrafish, and
humans (11). All integrins have a basic structure [Figure 5], with an intracellular domain that
interacts

Figure 5. This schematic shows the structure of a basic integrin. It is transmembrane with the
intracellular portion highlighted in yellow, and the extracellular portion highlighted in green.
http://atlasgeneticsoncology.org/Genes/Images/ITGA6Fig2.png

with
signals in
the

cytoplasm and cytoskeletal elements, a very thin transmembrane domain, and an extracellular
domain that acts as a receptor for binding to several different molecules, proteins and to relay
signals between cells (11). Integrins are distinguished from other integral proteins and receptors
on the cell surface in that they are bidirectional. This directionality occurs because integrins are
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able to transmit signals from the extracellular to intracellular domain and vice versa, leading to
their large roles in immune responses, hemostasis, and overall cell development (11). While
there are several different types of integrins including 18α and 8β subunits, ITGA6, comprised of
α6β1 and α6β4, have received special attention due to its role in tumor development (11).
2.2 ITGA6 in Angiogenesis
Angiogenesis is the formation of blood vessels that grow from the tumor into the blood
stream. These blood vessels allow cancer cells to migrate to other organs. In order for
angiogenesis to occur, proangiogenic factors are essential (5). In a study using hindlimb ischemia
as a model for peripheral arterial disease (PAD), researchers found ITGA6 levels of expression
were increased by vascular endothelial growth factor and fibroblast growth factor, two major
proangiogenic factors (5). Once there were high levels of gene expression, in vitro vascular tube
formation was enhanced significantly (5). This study concluded that high levels of ITGA6 are
needed in order to make the blood vessels that stem from the tumor (5). Another study
researching how angiogenesis occurs found that upregulation of ITGA6 induces the endothelial
cells to begin vasculogenesis (12). A study using human endothelium cells (EA cells) that
closely resemble vascular endothelium cells, saw an in vitro formation of a network tube like
structures, favoring blood vessels and the cellular process, angiogenesis (13). The experiment
concluded that a G-protein mediated signal was needed in order to form the tube structures. With
this information, they used pertussin toxin (PT), as means to block the signal, and ultimately
block angiogenesis (13). However, the researchers saw that PT was able to modestly block
angiogenesis, but when monoclonal antibodies against ITGA6 were used in the medium, the
results saw that tube like formation was completely block. Scientists concluding that ITGA6 was
the protein of most influence in angiogenesis (13). Lastly, an experiment was conducted based
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off the previously supported hypothesis that tumors have cells with increased basic fibroblast
growth factor (bFGF), one molecule that initiates that increased formation of blood vessels (14).
It was found that in cells with bFGF, there was severe upregulation of α6β1, α6β4 and other
integrins. These cells also had much better adherence to laminin, fribonection, and collagen 1,
prime factors thought to have a role in tumor progression (14). The experiment concluded that
integrins, ITGA6 specifically, led to increase angiogenesis in the endothelial cells (14). In
conclusion, several research groups have concluded that ITGA6 upregulation plays a significant
role in angiogenesis; however, scientists have not yet concluded what the increased amounts of
ITGA6 exactly do in angiogenesis and why normal levels of the same protein do not seem to
have an impact (14).
2.3 ITGA6 in Metastasis
Metastasis is the dissemination of cancer cells throughout the body via blood vessels
created during angiogenesis, accounting for approximately 90% of all deaths. In metastasis,
several researchers have looked in-depth into how ITGA6 is accommodating this largely
important factor of cancer (15). In a study using human prostate cancer cells and mice as a
model, researchers knocked down the levels of ITGA6 using a blocking-function antibody (15).
Their results showed that there was only 40% of the metastatic tumor progression in comparison
to the control (did not receive the antibody) which saw 80% progression. The study concluded
that ITGA6 played a role in inducing metastasis (15). A different experiment wanted to discover
if there was a biomarker for the highly metastatic cancer of the female breast. Their research saw
that ITGA6 had high levels of expression in brain metastasis (16). They concluded that gene
profiling to look for the levels of expression for ITGA6 would be an important biomarker for
early diagnosis for cancer, and hopefully being able to treat the cancer before it begins (16).

12

Another study investigating the effects of metastasis and ITGA6 used esophageal squamous
cancer cells as a model (17). The results of the experiment concluded there were significant
levels of ITGA6 and CTHRc1, a protein found at high levels in esophageal cancers, in the cells
at a rate of 71% (17). These cells and the expression of the two proteins were compared to the
levels in normal esophageal cells using immunohistochemistry, and they were able to confirm
lower levels of expression in the normal cells (17). They also concluded that metastatic cells in
squamous population also had higher levels, 50% higher, of ITGA6 (17). They concluded that
ITGA6 has a large role in metastasis of squamous cancer cells, and may be a potential marker of
esophageal cancer (17). Lastly, an experiment was conducted to study the role of SNAI1 protein
and its role in epithelial-mesenchymal transition (EMT), an important factor in metastasis (18).
Using prostate cancer cell lines, LNCaP and PC3, they saw that knockdown of the SNAI1 protein
also led to downregulation of ITGA6 which in turn, led to decreased metastasis, and overall
cancer cell death in both lines (18). Researchers saw that ITGA6 played a large role metastasis
(18). In conclusion, we have been able to determine that ITGA6 levels can be indicative of
metastasis, but more research needs to be directed into the correlation of these levels and
increased progression and susceptibility (18).
2.4 ITGA6 in Cancer Stem Cells
Cancer stem cells are self-renewing cells that co-exist within normal cancer cell
populations and give rise to secondary tumors and relapses in the disease. In the last factor of
cancer, CSCs, ITGA6 has also been seen to play a profound role in the stem cell’s ability to
control angiogenesis and metastasis (19). In an experiment studying the CSCs responsible breast
cancer’s high metastasis rate, they used an in vitro knockdown approach to reduce gene
expression of ITGA6. They saw a large decrease in secondary tumors, as well as, the loss of
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renewal ability in the CSCs (19). Another study in prostate cancer focused on what gave rise to
the cancer (19). The scientists used gene profiling of progressed human cancer cells to see if
there were biomarkers of the cancer (19). The profile showed ITGA6 as an important biomarker
due to its relatively high amounts of gene expression in the entire prostate cancer population and
in the sub-population of prostate CSCs (20). In CSCs, high levels of ITGA6 have been seen in
several cancers to play a role in CSC population, but they have not yet seen determined what
these high levels contribute to (20). In conclusion, research has been able to discovery that
ITGA6 upregulation, high levels of gene expression plays a role in proangiogenesis, metastasis,
and cancer stem cell markers (20).
2.5 Down Regulation of ITGA6
In another direction, some researchers have even looked into what effects low levels of
ITGA6 can lead to in cancer progression. While high levels of ITGA6 has been found to promote
tumor progression, mutations in ITGA6 also can lead to tumor susceptibility and progression
(21,22). A study in papillary thyroid cancer found that a single missense mutation, a single
change in a codon that leads to a different mutation, may be responsible for the cancer (21). This
hypothesis was also supported by a study in prostate cancer in which five different intron single
nucleotide polymorphisms in the ITGA6 gene led to increased progression in the cancer (22).
These studies support the notion that even low levels of ITGA6 can lead to cancer progression
and susceptibility, a contradicting conclusion to high levels also increasing progression (21,22).
2.6 ITGA6’s Potential Diagnostic/Therapeutic Strategy
In all, we understand that high levels of ITGA6 can promote any factor of cancer. In
another aspect of ITGA6, research has suggested that mutated ITGA6 can lead to lower levels of
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progression in comparison to truncated or cleaved ITGA6. Cancer researchers know that low
levels of ITGA6 can also lead to progression and susceptibility, two very contradicting
statements. However, what we do not yet understand is how exactly both high and low levels
ITGA6 lead to cancer susceptibility and how a mutated gene can decrease cancer progression.
In conclusion, ITGA6’s ability to decrease tumor progression can be examined and
isolated to potentially provide a therapeutic strategy of minimalizing the cancer or serving as a
biomarker for the susceptibly to different cancers. With this information, the race to find a cure
for cancer will be greatly accelerated.
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3. Hypothesis/Predictions
In my study, I plan to study the two questions: 1) will high or low levels of ITGA6
protein induce tumor metastasis. We predict that increased levels of ITGA6 will induce tumor
metastasis. 2) will cleaved, extracellular ITGA6 induce tumor metastasis. We hypothesize
that cleaved ITGA6 will induce tumor metastasis, also. The second question stems from in vitro
cell culture, where they have seen a cleaving mechanism of the protein. With this mechanism, an
enzyme cleaves the extracellular portion of the protein, and this product is expressed in the
microenvironment. A cell culture assay does not allow for the cell-to-cell interactions that are
present in the tumor microenvironment, and therefore, this mechanism needs to be explored in an
in vivo model to confirm the mechanism and to determine its effects in tumor progression. We
pTo explore both questions, we will use a Zebrafish tumor xenograft model. In this model, we
will transplant human prostate cancer cells into zebrafish embryos, as well as use ITGA6 RNA to
manipulate the levels of human ITGA6 in the zebrafish.
ITGA6 will be used will be regulated in three constructs, full length RNA, truncated
RNA, and mutated RNA. To study the first question, full length mRNA will be compared to
embryos with the unchanged or regular levels of ITGA6. Full length mRNA [Figure 6]

Figure 6. In the FL-ITGA6 construct, there
is an increase of the protein on the cell
surface.
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was created by overproducing the extracellular domain of the protein on the surface of the cell.
Instead of having only one extracellular domain portion, like that of the control embryos, full
length embryos will have several extracellular domain protein, in order to study these effects on
tumor progression. We hypothesize increase levels of ITGA6 will induce tumor metastasis and
overall tumor development.
To answer the second study, mutated mRNA and truncated mRNA will be used to model
the in vitro mechanism. Mutated mRNA [Figure 7.A] was translated with a mutation in the
cleaving site of the enzyme that is believed to cut the extracellular domain of ITGA6. With this
mutation, the cleaving cannot occur, and the extracellular domain stays attached to the cell
surface. In truncated mRNA [Figure 7.B] only the extracellular domain of the protein is
produced, so that there is no ITGA6 on the surface of the cell, and the protein is able to be
dispersed within the ECM and microenvironment of the tumor. We believe truncated protein will
increase tumor metastasis and mutated ITGA6 will lead to decreased levels of tumor metastasis
and overall tumor development.

Figure 7.A

Figure 7.B

Figure 7.A shows the mutated ITGA6 construct, in which the cleaving site was mutated, so the integrin was fixed
to the cell surface.
Figure 7.B The α6p construct only expresses the extracellular component of the integrin, in which it has been
cleaved.
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Materials
4. Cell Culture
4.1 Inoculation
Prostate cancer cells, line PC-3, from GeneScript® were obtained from another lab on
campus. These cells are labeled immortalized cell lines, as they are more homogenous and stable
than primary cancer cells in in vitro assays. Cell culture must be conducted in a biosafety level
two lab, with a biosafety cabinet with laminar flow, due to their potential pathogenic properties.
To begin growing the cells, one bottle of Opti-Mem 1X w/ glutamine w/ HEPES w/o| phenol red
media, five milliliters of penicillin streptomyocin (P/S), and 50mL of Fetal Bovine Serum (FBS)
are placed into a 37⁰C water bath for 30 minutes. While the contents are heating, aseptic
techniques were conducted. The hood was opened half way and sprayed with 70% ethanol. The
70% ethanol was dried using paper towels, and the appropriate amount of 10 mL and 25 mL
pipettes for the experiment were obtained and sprayed with 70% ethanol before being placed
inside of the hood. When the media had 10 minutes left, one vial, containing one milliliter of
cells, was removed from liquid nitrogen and placed into the 37⁰C water bath. All contents were
taken out of the water bath after ten minutes, and sprayed with 70% ethanol before being placed
inside the hood. The growth media was prepared by adding 50mL of FBS and five milliliters of
P/S to one bottle of growth media. The solution was pipetted up and down, and placed aside.
Two T-75 cell culture flasks from Corning® were obtained, sprayed with 70% ethanol and
placed inside the hood. 20mL of media were pipetted into each cell culture flask, and 500uL of
cells were pipetted into each flask. The flasks were labeled with the initials, date, and passage
one, signifying its first splitting from the original line. The flasks were placed into the 37⁰C

18

incubator. To clean the hood, all contents and pipettes were placed into the biohazard waste bag
and all glassware was placed into the sharps container. The media was placed in the four degree
Celsius refrigerator, and the hood was again sprayed with 70% ethanol. The ethanol was dried,
then hydrogen peroxide was sprayed in the hood. The hood was dried again, closed, and the UV
light was turned on for one hour. The flasks were checked every 24 hours until confluency
reached 60-75%, usually spanning five to six days.
4.2 Harvesting
When cells have reached confluency, they are ready to be split and used for experiments.
To begin splitting, growing media and 1X phosphate saline buffer (PBS) were placed into the
37⁰F water bath for 30 minutes. While the media and PBS heated, aseptic techniques were again
performed. 70% ethanol was sprayed in the hood and the pipettes were sprayed before being
placed into the hood. The cell flasks were retrieved from the 37⁰C incubator and sprayed before
entering the hood. After 20 minutes, 1X trypsin-EDTA was placed into the warm water bath.
After 10 minutes, all contents were taken out of the water bath, sprayed and put inside the hood.
A PBS-1X trypsin solution was made by adding 3mL of 1X PBS to 7mL of 1X-trypsin EDTA
(1.5mL PBS and 3.5mL trypsin for one flask), and they were mixed by pipetting up and down.
The solution was placed to the side, and the vacuum was used to discard of the previous media
from each flask. Next, 10mL of PBS was added, and the flasks were rocked back and forth to
wash all walls. The PBS was discarded, and 5mL of the trypsin-PBS solution was added to each
flask. The flasks were then placed back into the incubator for 15 minutes. The cells were taken
out every five minutes and tapped gently on the palm to detach the cells from the bottom. After
15 minutes, the cells were sprayed and placed back into the hood. Eight milliliters of fresh media
was added to each flask, then the 13mL solution was transferred to a 15 mL Eppendorf tube. 20
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mL of fresh media were added to the flasks. The flasks were labeled with initials, date, and
passage 2 (or corresponding passage) and placed back into the incubator.
4.3 Counting and Labeling of Cells for Experimentation
To use the cells for implantation, the 15mL solutions were counted using a
hemocytometer. 10uL of the solution was pipetted on to the hemocytometer, and each of the four
quadrants of the hemocytometer were counted, divided by four and multiplied by a factor of 104.
Next, this concentration was used to determine final volume needed to achieve a desired
concentration of one million cells per milliliter. This final volume was pipetted from the solution
into a new falcon tube, and centrifuged at 970 RPM for five minutes. The supernatant was
discarded and the pellet of cells was broken up. Next, the final volume of R-1 media, media
without FBS and P/S, was added to the cells. Next, DiI, red in color, was added to the solution
(5uL per final volume), and pipetted up and down. The solution was put in the incubator for 15
minutes, and then centrifuged at 500 RCF for two minutes. The supernatant was discarded, pellet
broken up, and the final volume, calculated using C1V1=C2V2, of fresh media was added to the
cells. The cells are viable for up to four hours in the incubator.
4.4 Zebrafish Husbandry
Zebrafish are a great non-mammalian cancer model for several reasons. Zebrafish are
widely used as a cancer model, because they can spontaneously develop almost any type of
cancer that are present in humans (23). They also can mimic the severity of a cancer, such as a
cancer that shows little metastasis versus a cancer that is highly metastatic. With this, the
development [Figure 8] of the embryo is ex-utero and transparent which allows for observation
of the cancer progression in a live model without harming or killing the embryo. Zebrafish are
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also not adversely affected by genetic knockouts and expression of transgenes, which are
necessary techniques in regulating levels of human ITGA6 expression (23). Zebrafish are also a
better tool than other models such as mice, because they are cheaper and can be studied within a
five day post injection period, while a mouse would have to take one to two months to fully
develop the cancer. They can also be injected with fluorescent cells [Figure 9] to see the
progression of
cancer and ITGA6
via imaging
Figure 8. The figure
shows the
development of the
zebrafish from 0hpf
to five days old.
http://gos.sbc.edu/n/
nv/graphics/nv6.gif

software in vivo. In
all, a zebrafish
tumor xenograft
model would be
the most efficient
model to study the
progression and
effects of prostate
cancer and
different levels of
ITGA6 of a human.
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A

B

Figure 9. Panel A shows the injection microscope used in injecting ITGA6 RNA and human prostate
cancer cells. Panel B shows where the ITGA6 RNA is injected into an embryo at 0hpf.
A. http://zfish.nichd.nih.gov/Intro%20Page/intro_pix/angio2.jpg
B. https://i.ytimg.com/vi/7N83MzkzIns/hqdefault.jpg

The zebrafish provided in the experiment were obtained from a self-maintained
laboratory on campus. The fish were kept up to standard using approved protocols, and
permission was obtained following an IUPAC proposal. To breed the fish to yield fertilized eggs,
two separate tanks are set up, and eggs are collected the following morning. Transgenic fish of
the strain, Tg (fli l a: GFP) were used in the making of the xenograft model, as the fli la
expresses a green fluorescent protein in the blood vessels.
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4.5 Manipulation of ITGA6
4.5.1 RNA Microinjections
Synthetic RNA constructs were made creating full length, mutated, and truncated forms
of ITGA6.
The
sequences
for each
construct
and pCS2+
vector
[Figure 10]
were
determined
in vitro and
sent to
Genscript®
for
Figure 10. pCS2+ vector used to make ITGA6 constructs (full length, mutated, and truncated) using
restriction enzymes ClaI, XbaI, BamHI, and EcoRI.
http://www.snapgene.com/resources/plasmid_files/image_consortium_plasmids/pCS2+/pCS2+_1x.png

synthesizing. In order to confirm the presence of each RNA using immunohistochemistry, a
MYC tag was added to the C-terminus of the protein.
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The three RNA injections were made to change the protein’s normal structure and
function. Full length RNA is altered to produce more of the protein on the surface of the cell.
Truncated RNA mimics the in vitro cleaved protein. With this construct, the protein’s
transmembrane structure is found in the microenvironment of the tumor, instead of the plasma
membrane of the cell. The last construct, mutated ITGA6 RNA, mimics the in vitro non-cleaved
product. With this, the protein’s site of enzymatic cleavage is mutated, allowing the enzyme to
not be able to cut the protein. In this construct ITGA6 cannot be removed from the cell surface.
4.5.2 ITGA6 Knockdown
The “knockdown” approach used in the experiment was the morpholino technique. This
approach leads to no gene expression of ITGA6 in the zebrafish cell. Morpholino powder was
ordered from Gene Tools LLC, and resupsended in nuclease free water. The solution was then
diluted in nuclease free water and dextran tetramethyl-rhodamine. The morpholinos were titrated
and were then ready to be used in the experiment.
4.6 Microinjections
At zero hours post fertilization (hpf), the embryos are injected with their respective RNA
or antisense RNA. Needles for injection are made using three and one half inch Drummond
replacement tubes (#3-000-203-g/x) in a Model P-1000 Fleming/Brown Micropipette Puller. The
solution for each construct is in 0.2% phenol red is pipetted into the needle, and oil is added to
the needle to remove the remaining air. The tip of the needle was broken using micro tweezers
and then injected, approximately three nanograms per nanoliter, into the embryo using a
Nanoject II™ Auto-Nanoliter Injector. The embryos are then placed into the incubator, and will
be ready in 24 hours for the second round of injections.
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Next, the cultured prostate cancer cells will be used to inject into the embryo. The cells,
at a concentration of 1,000,000 cells/mL, were loaded into the microinjection needle. Oil was
then injected into the needle to remove air, and the tip of the needle was broken using micro
tweezers. The zebrafish are then taken out of the incubator, and placed into tricane, a light
anesthetic. The cancer cells are injected into the embryos, and then are washed with embryo
medium to take away the effects of tricane. The embryos are then placed back into the incubator.
4.7 Observations and Confocal Imaging
4.7.1 Observations
After injections, the embryos are assayed for metastasis and angiogenesis for two days
(observations beginning when embryos are 48hpf). To conduct the assays, the embryos are taken
out of the incubator and placed in tricane, a light anesthetic. The embryos are observed for
angiogenesis looking at the embryos under the GFP 470 filter. This filter is used, because the
blue fluorescence allows the blood vessels to illuminate green, allowing for easy visualization of
the red-labeled cancer cells. The Rhodamine filter is used to observe metastasis, as this filter
fluoresces green and illuminates the cancer cells in red. The embryos are then taken out of
tricane, washed with embryo medium, and placed back into the incubator. Assays are then
performed again, approximately 24 hours later, under the same conditions.
4.7.2 Confocal Imaging
After observations on the second day, confocal imaging begins. Confocal imaging allows
for both blue and green fluorescence enabling the visualization of the red cancer cells in the
green blood vessels. Two embryos showing metastasis and angiogenesis and one without is
imaged per treatment. To begin confocal imaging, each embryo is live mounted onto a slide.
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Live mounting is conducted by placing the embryo in tricane, a light anesthetic, for
approximately one minute, or until it is not moving. It is then pipetted into a drop of methyl
cellulose that is in the depression of a depression slide. The embryo is manipulated so that the
body is on its side, with the head pointing to the right. It is then placed in the laser confocal
microscope. The microscope is set to the 488 wavelength, and a time lapse video of
approximately one minute and a half is created. The embryo is washed with embryo medium,
placed back into the incubator, and the next fish was imaged. After all imaging is conducted, the
embryos are fixed with 4% Paraformaldehyde for preservation.
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Results and Discussion
Truncated ITGA6 (α6p)

Mutated ITGA6

ITGA6 Expression
Schematic

FL ITGA6

B

C

E

F

Zebrafish embryo @ 8
hpf

A

D

Figure 11. Panel A shows full length ITGA6 with increased protein on the cell surface. Panel B shows only the
extracellular portion of ITGA6 was produced, and Panel C shows a mutation in the cleavage siting, allowing the
protein to be non-cleavable. Panel D shows full length ITGA6 expression in an embryo at 8hpf. Panel E expresses
the cleaved protein in the microenvironment of the 8hpf embryo, and Panel F shows the mutated ITGA6 only on
the surface of the cells.

Using confocal imaging, we were able to visualize the expression of our ITGA6
constructs in the embryo. With the FL-ITGA6 embryos, we injected the full length ITGA6 RNA
into the embryo at 0hpf. After eight hours, we could see the expression of the protein the
embryo. We expected to see an increased amount of the protein in the embryo. We can see a lot
of red, signifying the protein, indicating the RNA expressed the correct phenotype. In the α6p
embryos, we expected to see less of the protein on the cell surface, and more in the
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microenvironment, as we only expressed the extracellular portion of the protein. We saw this
phenotype in the embryo. Lastly, we injected mutated ITGA6 RNA into the embryo, and we
expected to see integrin on the surface of the cell only, as we mutated the cleaving site for the
enzyme. We also saw this expression in the embryo. With these images, we were able to
conclude that our RNA constructs are expressing the correct phenotype.

Figure 11. In this panel, image A shows labeled with DiI-red prostate cancer cells used to inject into the
zebrafish to make the zebrafish tumor xenograft model. Image B shows the same cells under a fluorescence
light.

In order to create our humanized zebrafish tumor xenograft model, it was imperative to

A

B

use human prostate cancer cells to study the interactions between human integrin alpha 6 and
human cancer cells. The red flourescences of the cells allowed for clear visiblity of the tumor,
another feature important in study in vivo tumor progression.

28

A. Tumor Xenograft – No Metastasis

B. Tumor Xenograft – Metastasis

Figure 12. Image A portrays a fish with no metastasis. Panel B shows a fish with metastasis in the trunk.

The above embryos were imaged using confocal imaging. This was an important factor in
being able to clearly distinguish between metastatic and non-metastatic characteristics of each
embryo.
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Figure 13. The graph shows the average amount (%) of metastasis of the embryos from each group.
The number in bracket signifies how many total embryos were a part of the group. Each construct was
compared to the control, using a t-test. Significant p-values of <0.01 were found in the FL-ITGA6 and
α6p (truncated ITGA6) constructs.

The graph above measures the average percentage of tumor metastasis in five groups,
with the numbers in parenthesis representing how many where in each group. The control group
only received human prostate cancer cells as a measure to determine the metastasis of the cancer
cells without manipulation of ITGA6. The FL-ITGA6 embryos expressed an increased amount
of the protein on the cell surface. α6p fish expressed only the extracellular portion of the protein,
and the mutant ITGA6 embryos expressed a mutation that did not allow for the enzyme to
cleave, and therefore, was rooted to the cell surface. Lastly, we used a morpholino knockdown

approach in the Itga6 MO embryos to ablate the expression of integrin alpha 6. Using a t-test, we
compared each group to the control. We found a significant statistical p-value of <.01 when
comparing FL-ITGA6 to the control, suggesting that increasing ITGA6 induces tumor
metastasis. However, when comparing α6p to the control, we found a smaller, more statistically
significant p-value suggesting that truncated ITGA6 also induces tumor metastasis.

These results add clarity to what may be occurring in the microenvironment of the tumor.
When a normal cell has undergone transformation into a cancerous cell, a change in the
microenvironment allows the cell to lose its adhesion to the epithelial basement membrane. This
change also enables the cell to invade a blood vessel and metastasis to a new tissue, creating
secondary tumors. With these results, we suggest an increased amount or cleaved integrin alpha
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6 protein in the microenvironment are one of the changes allowing these cells to lose adhesion,
invade, and metastasize (16, 17, 18). With this, ITGA6 has been identified to be a biomarker
predicting several different cancers such as stomach, oral, prostate, and several more cancers
(24,25,26).

Looking further into the microenvironment of tumors, we speculated that signaling is the
major factor that allows for the changes to be able to lose adhesion and metastasizes. When there
is an increased amount of cleaved ITGA6 on the cell, we believe this allows for first, outside-in
then inside-out signaling, that allows for these tumorigenic properties. To begin, we believe that
outside-in signaling begins the changes. This type of signaling allows the cell to sense and
respond to the changes in their environment (27). The signaling begins with a specific ligand-

binding interaction, resulting in changes in the shape of the integrin (28). This changes allows for
modified protein interaction sites and increased ligand affinity, transmitting the signal into the
cell (27,29). We believe the signal the cell receives contains information that changes the
programming of the cell, leading to changes in the morphology and behavior of the cell. A
change in the morphology allows for an increased amount of membrane protrusions, making the
cell spiked and able to penetration surfaces (29). The change in behavior allows the cell to be
more aggressive and to gain increased motility, important factors in invading and moving
through a blood vessel.

Next, inside-out signaling occurs. This signaling pathway accounts for the ability for the
cell to regulate the activity of its integrin (27,28). Inside-out signaling occurs when other
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receptors send signals, activating intracellular signaling pathways. After this, the cytoplasmic
domain of the beta subunit binds specific cofactors, talin and kindlin, in the cell which activates
ligand-induced bind sites on the extracellular portion of the protein (28,29). We believe that a
specific substrate or interaction occurs which releases the enzymes into the extracellular matrix.
We focused on a particular group of enzymes, metalloproteinases (MMPs), which allows the cell

to degrade the extracellular matrix as it migrates and metastasizes (27,28,29)

To conclude, we believe that when a cell undergoes transformation into the cancer cell,
changes in integrin alpha 6, that either upregulates it or cleaves it, allows the cell to lose cell
adhesion to its tissue. Next, both outside-in and inside-out signaling pathways allow for the cell
to become more aggressive, and move through the extracellular matrix to invade blood vessels

and metastasize. With this, ITGA6 can be used a biomarker to detect the probability of these
changes occurring. We believe that combining ITGA6 genetic testing with early diagnosis of
cancer gives the best chances of completely eradicating or killing the cancer in its early stages. In
the future, we would like to conduct drug assays with ITGA6 to devise a preventative strategy to
cancer.
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